



NDA 022458/S-23

## SUPPLEMENT APPROVAL

Pfizer Inc.  
Attention: Deneen Stewart  
Director, Worldwide Safety and Regulatory  
500 Arcola Road  
Collegeville, PA 19426

Dear Ms. Stewart:

Please refer to your supplemental new drug application (sNDA) dated June 03, 2019, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Eleyso (taliglucerase alfa) for injection.

This Prior Approval supplemental new drug application provides for an update to Section 6.2 Immunogenicity of the US Prescribing Information based upon the results of PMR 1895-4.

### **APPROVAL & LABELING**

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jenny Doan, Regulatory Project Manager, at (301) 796-1023.

Sincerely,

*{See appended electronic signature page}*

Dragos Roman, M.D.  
Acting Director  
Division of Gastroenterology and Inborn Errors  
Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

#### ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

DRAGOS G ROMAN  
10/21/2019 06:25:38 PM